SAB Biotherapeutics
SABS
SABS
37 hedge funds and large institutions have $4.45M invested in SAB Biotherapeutics in 2022 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 9 increasing their positions, 7 reducing their positions, and 3 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more ownership
Funds ownership: →
34% less capital invested
Capital invested by funds: $6.78M → $4.45M (-$2.33M)
Holders
37
Holding in Top 10
–
Calls
–
Puts
–
Top Buyers
| 1 | +$946K | |
| 2 | +$424K | |
| 3 | +$122K | |
| 4 |
Millennium Management
New York
|
+$93K |
| 5 |
BlackRock
New York
|
+$79.7K |
Top Sellers
| 1 | -$170K | |
| 2 | -$91K | |
| 3 | -$9.97K | |
| 4 |
JPMorgan Chase & Co
New York
|
-$5.29K |
| 5 |
WAM
Wolverine Asset Management
Chicago,
Illinois
|
-$3.18K |